Management of Hypoproteinemia with Anasarca and Congestive Cardiac Failure

Initial Assessment and Monitoring

The European Society of Cardiology recommends immediate evaluation of vital cardiorespiratory functions including pulse oximetry, blood pressure, respiratory rate, and continuous ECG monitoring is essential in patients with hypoproteinemia and congestive cardiac failure 1
Laboratory assessments should include cardiac biomarkers, renal function tests, electrolytes, glucose, complete blood count, liver function tests, and thyroid function tests in patients with hypoproteinemia and congestive cardiac failure 2
Echocardiography should be performed within 48 hours to assess cardiac structure and function in patients with hypoproteinemia and congestive cardiac failure 2
Regular monitoring of electrolytes is crucial, with particular attention to hypo- or hyperkalemia in patients with hypoproteinemia and congestive cardiac failure 3

The European Society of Cardiology recommends loop diuretics should be administered concurrently with albumin to mobilize fluid and reduce anasarca in patients with hypoproteinemia and congestive cardiac failure 3
Monitor response to diuretic therapy through daily weight measurements and clinical assessment of edema in patients with hypoproteinemia and congestive cardiac failure 4

Identify and manage precipitating factors that may have led to cardiac decompensation in patients with hypoproteinemia and congestive cardiac failure 1
For patients with reduced left ventricular systolic function, the American College of Cardiology recommends initiate or optimize ACE inhibitors as first-line therapy 5
Add beta-blockers for stable patients with heart failure with reduced ejection fraction, as recommended by the American College of Cardiology 5
Consider spironolactone for advanced heart failure (NYHA Class III-IV), as recommended by the American College of Cardiology 5

If coronary artery disease is suspected, consider coronary angiography as it may improve prognosis in patients with hypoproteinemia and congestive cardiac failure 4
Avoid excessive diuresis before starting ACE inhibitor treatment in patients with hypoproteinemia and congestive cardiac failure 5
Avoid NSAIDs during ACE inhibitor therapy in patients with hypoproteinemia and congestive cardiac failure 5
Monitor for hypotension when starting ACE inhibitors or beta-blockers in patients with hypoproteinemia and congestive cardiac failure 5

An improvement in hemodynamic parameters alone may be misleading; look for concomitant improvement in symptoms (dyspnoea and/or fatigue) in patients with hypoproteinemia and congestive cardiac failure 3
Routine inotropic therapy should be reserved for severe episodes of heart failure as it increases mortality, as recommended by the American College of Cardiology 5
Avoid beta-blockers in patients with asthma, severe bronchial disease, or symptomatic bradycardia/hypotension, as recommended by the American College of Cardiology 5